-
A polygenic score predicts CKD across ancestries Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-11 Inga Steinbrenner, Anna Köttgen
-
Cellular senescence: the good, the bad and the unknown Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-03 Weijun Huang, LaTonya J. Hickson, Alfonso Eirin, James L. Kirkland, Lilach O. Lerman
-
Kidney disease as a medical complication of eating disorders Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-02 Leah Puckett, Shoshana Mehler, Philip Mehler
Kidney disease is an underappreciated medical complication of anorexia nervosa. Further research is needed to clarify the mechanisms that drive kidney disease in patients who restrict caloric intake or engage in purging. Education and awareness are also needed, because kidney disease is often under-recognized by these patients and their clinicians.
-
Restrictive fluid therapy and high-dose vitamin C in sepsis Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-01 Mark Philip Plummer, Rinaldo Bellomo
Two recent randomized trials provide evidence to guide the management of sepsis. The CLASSIC trial reports that restrictive fluid therapy has no mortality benefit compared to a standard regimen in patients with septic shock, whereas the LOVIT trial reports that high-dose intravenous vitamin C might be harmful in patients with severe sepsis.
-
A pathway of osmotic stress-induced necroptosis Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-01 Alberto Ortiz, Ana B. Sanz
-
Pervasive kidney health inequities for Māori require multi-level attention Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-29 David Tipene-Leach, Rachael Walker
Indigenous Māori experience inequitably high rates of kidney failure and lower rates of kidney transplant, pre-emptive procedures and home dialysis when compared to the New Zealand population as a whole. Prevention strategies in primary care, cultural safety training and routine clinical audit for renal practitioners alongside Indigenous people in governance, management and the clinical workforce would
-
Activation and regulation of alloreactive T cell immunity in solid organ transplantation Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-27 Charlotte Duneton, Pamela D. Winterberg, Mandy L. Ford
-
UTX regulates accumulation of lipids via kidney serine. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-26 Monica Wang
-
Stem cell-kidney transplantation in Schimke immuno-osseous dysplasia. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-25 Susan J Allison
-
Determining treatment response in lupus nephritis. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-25 Susan J Allison
-
Unmet care needs of minority groups on dialysis. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-25 Susan J Allison
-
Principles of human and mouse nephron development Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-22 Jack Schnell, MaryAnne Achieng, Nils Olof Lindström
-
Immunometabolic rewiring of tubular epithelial cells in kidney disease Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-07 Sanne van der Rijt, Jaklien C. Leemans, Sandrine Florquin, Riekelt H. Houtkooper, Alessandra Tammaro
-
Benefits of CoQ10 supplementation in patients with SRNS due to primary CoQ10 deficiency. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-01 Ellen F Carney
-
A single-cell atlas of DKD treatment responses. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-08-01 Ellen F Carney
-
The fibrogenic niche in kidney fibrosis: components and mechanisms Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-04 Li Li, Haiyan Fu, Youhua Liu
-
Salt substitution: opportunities and challenges for nephrology Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-24 Ewout J. Hoorn, Matti Marklund, Jason H. Y. Wu
-
Role of the cGAS–STING pathway in systemic and organ-specific diseases Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-22 Sladjana Skopelja-Gardner, Jie An, Keith B. Elkon
-
The effect of HIF on metabolism and immunity Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-20 Cormac T. Taylor, Carsten C. Scholz
-
Patient-centred clinical trial design Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-06 Allison Tong, Nicole Scholes-Robertson, Carmel Hawley, Andrea K. Viecelli, Simon A. Carter, Adeera Levin, Brenda R. Hemmelgarn, Tess Harris, Jonathan C. Craig
Patient involvement in clinical trial design can facilitate the recruitment and retention of participants as well as potentially increase the uptake of the tested intervention and the impact of the findings on patient outcomes. Despite these benefits, patients still have very limited involvement in designing and conducting trials in nephrology. Many trials do not address research questions and outcomes
-
Dietary protection of proximal tubules in diabetes. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-01 Susan J Allison
-
P3H2 in glomerular basement membrane regulation. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-01 Susan J Allison
-
Important roles of mechanical force and hydraulic pressure in kidney function. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-07-01 Susan J Allison
-
Extracellular vesicles in kidney disease Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-31 Cristina Grange, Benedetta Bussolati
Extracellular vesicles are released by the majority of cell types and circulate in body fluids. They function as a long-distance cell-to-cell communication mechanism that modulates the gene expression profile and fate of target cells. Increasing evidence has established a central role of extracellular vesicles in kidney physiology and pathology. Urinary extracellular vesicles mediate crosstalk between
-
Continuing kidney care in conflicts Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-30 Raymond Vanholder, Anja De Weggheleire, Dmytro D. Ivanov, Valerie Luyckx, Slim Slama, Mohamed Sekkarie, Mehmet S. Sever, Rukshana Shroff
The devastating effects of war are far-reaching and particularly affect people with kidney disease. The Ukrainian conflict has highlighted problems encountered in the provision of support for this vulnerable group. On the basis of these and previous experiences in massive disasters, we propose a sustainable action plan to prepare for similar logistical challenges in future conflicts.
-
Cardiac metabolic remodelling in chronic kidney disease Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-30 Nikayla Patel, Muhammad Magdi Yaqoob, Dunja Aksentijevic
Chronic kidney disease (CKD) affects millions of people globally and, for most patients, the risk of developing cardiovascular disease is higher than that of progression to kidney failure. Moreover, mortality owing to cardiovascular complications in patients with CKD is markedly higher than in matched individuals from the general population. This mortality was traditionally thought to be driven by
-
Bringing Pride to nephrology Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-20
June marks Pride Month — an event that aims to recognize and celebrate LGBTQ+ communities worldwide. However, it also provides an opportunity to highlight the challenges that LGBTQ+ colleagues and nephrology patients continue to face, and the need to address health inequities.
-
Transcatheter mitral valve repair in patients with CKD Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-06 Wendy McCallum, Mark J. Sarnak
A post hoc analysis of the COAPT trial suggests that transcatheter mitral valve repair for secondary mitral regurgitation is efficacious in patients with heart failure and chronic kidney disease. The intervention also reduced the risk of kidney failure, raising hypotheses regarding the mechanisms that link heart failure and loss of kidney function.
-
Interferon blockade in lupus: effects on antiviral immunity Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-06 Stefanie Steiger, Hans-Joachim Anders
Targeting type I interferon immune responses is a potential strategy for the treatment of systemic lupus erythematosus. Although a phase 2 clinical trial of anifrolumab did not meet its primary end point, further studies are needed to assess the effects of interferon blockade on flare rates of lupus nephritis. However, the observed higher risk of herpes zoster associated with anifrolumab use suggests
-
-
Our commitment to rigorous, constructive and inclusive peer review Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-02
At Nature Reviews Nephrology, we believe that peer review should be a rigorous, constructive and inclusive process. We are working to meet this aim through several initiatives.
-
Membranous nephropathy: new pathogenic mechanisms and their clinical implications Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-28 Elion Hoxha, Linda Reinhard, Rolf A. K. Stahl
Membranous nephropathy (MN) is characterized histomorphologically by the presence of immune deposits in the subepithelial space of the glomerular filtration barrier; its clinical hallmarks are nephrotic range proteinuria with oedema. In patients with primary MN, autoimmunity is driven by circulating autoantibodies that bind to one or more antigens on the surface of glomerular podocytes. Compared with
-
METTL3 contributes to the pathogenesis of AKI. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-01 Ellen F Carney
-
Treating mild chronic hypertension in pregnancy. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-01 Ellen F Carney
-
Role of glomerular endothelial cell fenestrations. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-06-01 Ellen F Carney
-
Advancing kidney health justice through gender-affirming care Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-26 Han E. Eckenrode, Joseph T. Flynn, Dinushika Mohottige
Advancing kidney health justice for all requires the kidney-care community to embrace gender-affirming care across the life course, including inclusion of gender minority individuals in research, thoughtful attention to sexual-orientation and gender-identity data collection, as well as the promotion of policies and practices that protect and provide comprehensive care to all patients.
-
Artificial intelligence-enabled decision support in nephrology Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-22 Tyler J. Loftus, Benjamin Shickel, Tezcan Ozrazgat-Baslanti, Yuanfang Ren, Benjamin S. Glicksberg, Jie Cao, Karandeep Singh, Lili Chan, Girish N. Nadkarni, Azra Bihorac
Kidney pathophysiology is often complex, nonlinear and heterogeneous, which limits the utility of hypothetical-deductive reasoning and linear, statistical approaches to diagnosis and treatment. Emerging evidence suggests that artificial intelligence (AI)-enabled decision support systems — which use algorithms based on learned examples — may have an important role in nephrology. Contemporary AI applications
-
The impact of the Russian–Ukrainian war for people with chronic diseases Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-20 Giorgina B. Piccoli, Giuliano Brunori, Loreto Gesualdo, Kamyar Kalantar-Zadeh
People with chronic diseases are at high risk of becoming innocent victims of the Russian–Ukrainian war, owing to interruption of their health care. More than 10 million Ukrainian people have left their homes and almost 5 million have left the country. Provision of kidney care for these refugees is an emerging challenge.
-
Ensuring health equity for sexual and/or gender minority individuals Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-20 Juan D. Salcedo-Betancourt, Samira S. Farouk, Yuvaram N. V. Reddy
People who identify as sexual and/or gender minority individuals face unique and challenging inequities in access to health care. They experience bias, discrimination and underinsurance, which limits their access to high-quality care (including for kidney disease). These inequities must be addressed through the provision of safe and inclusive environments, improved identification of disparities and
-
Supporting sexual and gender minority health-care workers Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-13 Mackenzie H. Holmberg, Suzanne G. Martin, Mitchell R. Lunn
Sexual and/or gender minority health-care workers are subject to the heteronormativity and cisnormativity of society and often face open discrimination. Empowering these individuals to bring their full, authentic selves to work so that they can serve their patients and institutions with the totality of their strengths requires institutes and cisgender or straight allies to support LGBTQ+ communities
-
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-13 Viyaasan Mahalingasivam, Guobin Su, Masao Iwagami, Mogamat Razeen Davids, James B. Wetmore, Dorothea Nitsch
Over the course of the COVID-19 pandemic, numerous studies have aimed to address the challenges faced by patients with kidney disease and their caregivers. These studies addressed areas of concern such as the high infection and mortality risk of patients on in-centre haemodialysis and transplant recipients. However, the ability to draw meaningful conclusions from these studies has in some instances
-
COVID-19 vaccine hesitancy Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-12 Eve Dubé, Noni E. MacDonald
The COVID-19 pandemic has highlighted the vital role of vaccination in preventing life-threatening diseases and improving global health. Understanding and addressing the concerns of vaccine-hesitant individuals, including those with chronic diseases, is key to increasing vaccine acceptance and uptake.
-
Drosophila melanogaster: a simple genetic model of kidney structure, function and disease Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-11 Julian A. T. Dow, Matias Simons, Michael F. Romero
Although the genetic basis of many kidney diseases is being rapidly elucidated, their experimental study remains problematic owing to the lack of suitable models. The fruitfly Drosophila melanogaster provides a rapid, ethical and cost-effective model system of the kidney. The unique advantages of D. melanogaster include ease and low cost of maintenance, comprehensive availability of genetic mutants
-
Glomerular hyperfiltration Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-01 Monica Cortinovis, Norberto Perico, Piero Ruggenenti, Andrea Remuzzi, Giuseppe Remuzzi
Circulating blood is filtered across the glomerular barrier to form an ultrafiltrate of plasma in the Bowman’s space. The volume of glomerular filtration adjusted by time is defined as the glomerular filtration rate (GFR), and the total GFR is the sum of all single-nephron GFRs. Thus, when the single-nephron GFR is increased in the context of a normal number of functioning nephrons, single glomerular
-
A recombinant fusion protein clears IgA deposits. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-01 Ellen F Carney
-
Kidney complications of parasitic diseases Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-03-28 Elizabeth De Francesco Daher, Geraldo Bezerra da Silva Junior, Mayuri Trivedi, Tarek Fayad, Nattachai Srisawat, Sanjeev Nair, Padet Siriyasatien, Marcus Vinícius Guimarães de Lacerda, Maria Alice Sperto Ferreira Baptista, Mahesha Vankalakunti, Vivekanand Jha
Parasitic agents have been known to cause human disease since ancient times and are endemic in tropical and subtropical regions. Complications of parasitic diseases, including kidney involvement, are associated with worse outcomes. Chagas disease, filariasis, leishmaniasis, malaria and schistosomiasis are important parasitic diseases that can damage the kidney. These diseases affect millions of people
-
Circulating osteopontin mediates acute kidney injury-induced respiratory failure. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-01 Ellen F Carney
-
Role of pericytes in ischaemia-reperfusion injury. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-01 Ellen F Carney
-
Anti-tumour antibody-producing plasma cells disseminate from tertiary lymphoid structures. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-05-01 Ellen F Carney
-
Mapping the human kidney using single-cell genomics Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-03-17 Felix Schreibing, Rafael Kramann
The field of single-cell genomics and spatial technologies is rapidly evolving and has already provided unprecedented insights into complex tissues. Major advances have been made in dissecting the cellular composition and spatiotemporal interactions that mediate developmental processes in the fetal kidney. Single-cell technologies have also provided detailed insights into the heterogeneity of cell
-
Delivering on the potential of measuring nephron number in the clinic Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-03-09 Kevin M. Bennett, Edwin J. Baldelomar, Jennifer R. Charlton
Decades of research have revealed that nephron number is a crucial determinant of kidney health. However, a lack of appropriate tools has limited these studies to ex vivo analyses. For the first time, techniques are emerging that might enable the use of functional nephron number as a biomarker in living humans.
-
Antibodies against Neisseria in IgA nephropathy. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-01 Monica Wang
-
DPEP1 mediates neutrophil and monocyte influx. Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-04-01 Monica Wang
-
CKD-specific ASCVD risk prediction tools Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-25 Monica Wang
-
PKM2-induced protection from hyperglycaemia Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-25 Monica Wang
Diabetes increases the risk of developing kidney disease, but some patients may be protected. Having noted higher pyruvate kinase M2 (PKM2) in protected patients (patients with diabetes but without kidney disease), Fu et al. induced diabetes in mice overexpressing Pkm2 in podocytes. Compared with wildtype controls, transgenic mice had less diabetesinduced glomerular pathology and metabolic impairment
-
The evolving story of apolipoprotein L1 nephropathy: the end of the beginning Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-25 Parnaz Daneshpajouhnejad, Jeffrey B. Kopp, Cheryl A. Winkler, Avi Z. Rosenberg
Genetic coding variants in APOL1, which encodes apolipoprotein L1 (APOL1), were identified in 2010 and are relatively common among individuals of sub-Saharan African ancestry. Approximately 13% of African Americans carry two APOL1 risk alleles. These variants, termed G1 and G2, are a frequent cause of kidney disease — termed APOL1 nephropathy — that typically manifests as focal segmental glomerulosclerosis
-
Epidemiology of haemodialysis outcomes Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-22 Aminu K. Bello, Ikechi G. Okpechi, Mohamed A. Osman, Yeoungjee Cho, Htay Htay, Vivekanand Jha, Marina Wainstein, David W. Johnson
Haemodialysis (HD) is the commonest form of kidney replacement therapy in the world, accounting for approximately 69% of all kidney replacement therapy and 89% of all dialysis. Over the last six decades since the inception of HD, dialysis technology and patient access to the therapy have advanced considerably, particularly in high-income countries. However, HD availability, accessibility, cost and
-
Potential SARS-CoV-2 kidney infection and paths to injury Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-21 Luise Hassler, Daniel Batlle
Although direct kidney infection by SARS-CoV-2 remains controversial, a study based largely on autopsies shows increased tubulointerstitial fibrosis in patients with COVID-19 and suggests direct kidney infection. Moreover, in human kidney organoids, SARS-CoV-2 infection upregulates several pro-fibrotic and pro-inflammatory pathways.
-
The nephropathy of sickle cell trait and sickle cell disease Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-21 Kenneth I. Ataga, Santosh L. Saraf, Vimal K. Derebail
Sickle cell syndromes, including sickle cell disease (SCD) and sickle cell trait, are associated with multiple kidney abnormalities. Young patients with SCD have elevated effective renal plasma flow and glomerular filtration rates, which decrease to normal ranges in young adulthood and subnormal levels with advancing age. The pathophysiology of SCD-related nephropathy is multifactorial — oxidative
-
Shifting narratives in health care from resilience to redress and resistance Nat. Rev. Nephrol. (IF 42.439) Pub Date : 2022-02-17 Karthik Sivashanker, Cheri Couillard
Dominant narratives that describe the power of individual-level resilience underplay the long-lasting consequences of structural violence and perpetuate harms to historically marginalized patients and communities. It is time to update our approaches and narratives by addressing the root causes of inequities through redress and collective resistance to create the equitable conditions needed for communities